Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients

Arvind Gharbharan*, Corine H. GeurtsvanKessel, Carlijn C E Jordans, Marc Blaauw, Marjolein van der Klift, Robert-Jan Hassing, Marijn Smits-Zwinkels, Maaike Meertens, Ella C van den Hout, Anne Marie de Man, Ilse Hageman, Susanne Bogers, C. Ellen van der Schoot, Francis Swaneveld, Adam A Anas, Casper Rokx, Bart J A Rijnders

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)
35 Downloads (Pure)

Abstract

Twenty-five B-cell-depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.

Original languageEnglish
Pages (from-to)1271-1274
Number of pages4
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume74
Issue number7
Early online date22 Jul 2021
DOIs
Publication statusPublished - 1 Apr 2022

Bibliographical note

Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Fingerprint

Dive into the research topics of 'Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients'. Together they form a unique fingerprint.

Cite this